Presented study included human blood from heathy patients and from patients with BRCA mutation. Raman spectroscopy can be used for BRCA mutation detection and bioanalytical characterization of pathologically changed samples. The aim of this study is to evaluate the Raman biomarkers to distinguish blood samples from healthy patients and from patient with BRCA mutation by Raman spectroscopy. We have proved that Raman spectroscopy is a powerful technique to distinguish between healthy blood and blood with BRCA mutation and to characterize biochemical composition of samples. Partial Least Squares Discriminant Analysis yielded effective and comparable samples classification based on vibrational features. The sensitivity and specificity obtained from PLS-DA have been over 86.5%. The obtained results confirm clinical potential of Raman spectroscopy in oncological diagnostics.

The authors have declared no competing interest.

This work was supported by the National Science Centre of Poland (Narodowe Centrum Nauki, UMO-2019/33/B/ST4/01961).

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

All experiments were conducted in accordance with relevant guidelines and regulations of the Bioethical Committee at the Medical University of Lodz, Poland (RNN/17/20/KE). The experimental protocols were approved by Bioethical Committee at the Medical University of Lodz, Poland (RNN/17/20/KE).

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

All data produced in the present study are available upon reasonable request to the authors